These anti-HSPG strategies and available agents give great potential to future tauopathy treatments, exemplified by a recent study from Naini et al. showing that surfen and oxalyl surfen decreased tau hyperphosphorylation and mitigated neuron deficits in vivo in a zebrafish model of tauopathy [160]. The gene discussed is HSPG2; the disease is tauopathy.